Zalicus Inc. discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. We apply our selective ion-channel modulation platform and our combination high throughput screening capabilities to discover innovative therapeutics for both our internal product pipeline and our collaborators. Our pipeline includes Exalgo™ (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time and Synavive®, in Phase 2 development for rheumatoid arthritis. We believe that our novel product candidates, productive drug discovery platforms, drug development expertise, revenue-generating collaborations and financial resources provide a solid foundation for success.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
